Exelixis gains
Leerink Partners analyst Andrew Berens has maintained their neutral stance on EXEL stock, giving a Hold rating today. Andrew Berens has given ...
Zacks.com on MSN10h
Exelixis (EXEL) Soars 8.6%: Is Further Upside Left in the Stock?Exelixis (EXEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...
A federal judge in Delaware has ruled in favor of Exelixis in its Cabometyx patent fight with MSN Laboratories, effectively ...
RBC Capital analyst Gregory Renza maintained a Buy rating on Exelixis (EXEL – Research Report) yesterday and set a price target of ...
"Exelixis and MSD to trial cancer therapies together in clinical collaboration" was originally created and published by ...
On Monday, Exelixis Inc (EXEL) stock saw a modest uptick, ending the day at $26.24 which represents a slight increase of $0.01 or 0.04% from the prior close of $26.23. The stock opened at $26.23 and ...
Exelixis, Inc. (NASDAQ:EXEL – Get Free Report)’s stock price reached a new 52-week high during mid-day trading on Tuesday after Bank of America raised their price target on the stock from $30.00 to ...
Zacks.com on MSN1d
Exelixis, MRK Collaborate for Combination Studies on HNSCC and RCCExelixis, Inc. EXEL entered into a clinical development collaboration agreement with pharma giant Merck MRK to advance the ...
In addition to the legal success, Exelixis has received an upgrade from B of A Securities. The firm has maintained a Buy rating and raised the price target from $30 to $32. This optimistic outlook ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback